CVS Health is facing a probe into potential HIPAA violations related to the alleged use of patient data for lobbying purposes to prevent the passing of a Louisiana state bill that could affect its business interests. The bill in question, House Bill 358 (HB 358), proposes several amendments to current pharmacy laws in Louisiana. One of the proposed amendments is prohibiting providers in the state from operating as both pharmacy benefit managers (PBMs) and individual pharmacies.
A pharmacy benefit manager is an intermediary between drug companies and pharmacies that negotiates prices with the drug companies on behalf of employers and health plans. They often also manage pharmacy networks and operate mail-order pharmacies. PMBs are facing increased scrutiny over their business practices. The Federal Trade Commission (FTC) alleged that major PBMs have inflated drug prices to increase company profits, negotiating lower prices from drug companies, then marking up the drug prices at their pharmacies. According to an FTC report earlier this year, between 2017 and 2022, UnitedHealth Group’s Optum, CVS Health’s CVS Caremark, and Cigna’s Express Scripts increased the prices of medications for heart disease, cancer, and HIV at their affiliated pharmacies, boosting revenues by $7.3 billion in excess of the acquisition costs of the medications.
Several states have passed laws to rein in PMBs and limit their influence on drug pricing, and reducing the costs of medications is a key priority for the Trump administration. CVS Health and Cigna have filed lawsuits attempting to overturn a law implemented in Arkansas to this effect, and CVS Health is alleged to have engaged in lobbying to prevent HB 358 from being passed in Louisiana. If the bill is signed into law, it would have serious implications for CVS Health, which operates as the PBM CVS Caremark, as well as 119 CVS pharmacies in the state of Louisiana.
Louisiana Attorney General Liz Murrill launched an investigation of CVS Health earlier this year after receiving reports alleging CVS Health had sent large numbers of text messages to state employees and their families to lobby against the proposed legislation. One of the texts informed the recipients that if the bill is signed into law, their CVS Pharmacy could close, medication costs could rise, and their pharmacist could lose their job.
The texts included a link to a draft letter to lawmakers calling for them to reject the legislation. “The proposed legislation would take away my and other Louisiana patients’ ability to get our medications shipped right to our homes,” the letter read. “They would also ban the pharmacies that serve patients suffering from complex diseases requiring specialty pharmacy care to manage their life-threatening conditions, like organ transplants or cancer. These vulnerable patients cannot afford any disruption to their care – the consequences would be dire.” CVS Health has been accused of lying and using scare tactics to oppose the bill, which CVS Health denies.
In late June, AG Murrill filed three lawsuits against CVS Health alleging unfair, deceptive, and unlawful practices, which have harmed Louisiana patients, independent pharmacies, and the public at large. According to CVS Health spokesperson Any Thibault, the bill was proposed with no public hearing. “We believe we had a responsibility to inform our customers of misguided legislation that sought to shutter their trusted pharmacy, and we acted accordingly,” Thibault said. “Our communication with our customers, patients and members of our community was consistent with law.”
Now, a probe has been launched by two Republican lawmakers in response to the allegations that patient data was used for lobbying purposes, potentially in violation of the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule. House Committee on Oversight and Government Reform Chairman James Comer (R-KY) and Subcommittee on Federal Law Enforcement Chairman Clay Higgins (R-LA) wrote to CVS Health President and CEO David Joyner, demanding answers about how patient data has been used.
“This text message campaign raises ethical and potential legal issues if indeed CVS Pharmacy used confidential patient information, obtained through a state contract, to lobby against H.B. 358,” wrote the lawmakers. “The inflammatory and misleading text messages—which included threats of pharmacy location closures, increased prescription costs, and loss of service providers—sought to encourage CVS Pharmacy customers to contact Louisiana lawmakers to oppose the bill. This is concerning because CVS Pharmacy must comply with the Health Insurance Portability and Accountability Act (HIPAA) to access confidential patient information.”
The lawmakers explained in the letter that the HIPAA Privacy Rule does not expressly permit the use of patient data for political advocacy or lobbying, and that patient authorization would be required for such uses, pointing out that it appears that the mass texting capabilities used by CVS Health pharmacies for notifying patients about prescription updates and other individualized patient information has been used in a matter that may have violated HIPAA.
The lawmakers have requested documentation and copies of communications related to the use of patient and customer personal health information for the purposes of political advocacy or lobbying in Louisiana and all other states from January 1, 2020, to the present. They require a response by September 18, 2025.
The post CVS Health Faces HIPAA Probe Over Alleged Use of Patient Data for Lobbying and Political Advocacy appeared first on The HIPAA Journal.